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Medical	  treatment	  in	  chronic	  renal-­‐	  or	  kidney	  disease	  is	  aimed	  to	  improve	  the	  consequences	  of	  
the	  impaired	  renal	  function	  and	  to	  reduce	  progression	  of	  kidney	  disease.	  Medications	  may	  
improve	  the	  quality	  of	  live	  in	  patients	  with	  kidney	  disease	  or	  may	  prolong	  survival;	  however	  they	  
can	  not	  cure	  the	  patient.	  Different	  organ	  systems	  are	  affected	  by	  kidney	  disease	  and	  specific	  
treatments	  for	  these	  organ	  systems	  are	  used	  to	  ameliorate	  the	  situation	  of	  the	  patient.	  
	  
Definition	  
Renal	  disease	  or	  kidney	  disease	  simply	  describes	  damage	  to	  the	  kidneys.	  The	  damage	  may	  be	  
acute	  or	  chronic.	  Acute	  kidney	  injury	  leads	  to	  a	  rapid	  decline	  in	  renal	  function	  and	  to	  acute	  uremia,	  
whereas	  chronic	  kidney	  disease	  is	  already	  lasting	  for	  a	  long	  period	  of	  time.	  The	  term	  chronic	  is	  
used	  if	  the	  damage	  of	  the	  kidneys	  exists	  for	  at	  least	  3	  months.	  A	  decline	  in	  glomerular	  filtration	  
(GFR)	  rate	  is	  commonly	  associated	  with	  chronic	  kidney	  disease.	  It	  is	  assumed	  that	  3/4	  of	  the	  
nephrons	  must	  be	  damaged	  until	  azotemia	  can	  be	  detected	  by	  routine	  laboratory	  methods.	  	  
In	  this	  text	  we	  will	  focus	  on	  the	  medical	  management	  of	  the	  patient	  with	  chronic	  kidney	  disease.	  
Nutritional	  management	  of	  these	  patients	  is	  covered	  elsewhere.	  To	  get	  an	  idea	  of	  the	  severity	  a	  
staging	  system	  was	  established	  by	  the	  IRIS	  (International	  Renal	  Interest	  Society;	  www.iris-­‐
kidney.com).	  This	  staging	  system	  is	  based	  on	  the	  stable	  patient	  in	  which	  the	  values	  were	  
established	  on	  at	  least	  two	  occasions.	  
	  
Stages	  of	  chronic	  kidney	  disease	  in	  cats	  according	  to	  IRIS:	  
Stage	  1:	  Non-­‐azotemic:	   	   Creatinine	   	   	   	   	   <140	  mcmol/l	  
Stage	  2:	  Mild	  renal	  azotemia:	   Creatinine	   	   	   	   	   140-­‐249	  mcmol/l	  
Stage	  3:	  Moderate	  renal	  azotemia:	   Creatinine	   	   	   	   	   250-­‐440	  mcmol/l	  
Stage	  4:	  Severe	  renal	  azotemia:	   Creatinine	   	   	   	   	   >	  440	  mcmol/l	  
	  
Classification	  of	  proteinuria	  in	  cats	  according	  to	  IRIS:	  
Nonproteinuric	  (NP):	   	   	   Urine	  protein:	  creatinine	  ratio	  (UPC)	  	   <0.2	  
Borderline	  proteinuric	  (BP):	   	   UPC	   	   	   	   	   	   0.2-­‐0.4	  
Proteinuric	  (P):	   	   	   UPC	   	   	   	   	   	   >0.4	  
	  
Classification	  of	  blood	  pressure	  according	  to	  IRIS:	  
Substage	  0:	  minimal	  risk:	   	   systolic	  blood	  pressure	   	   	   <	  150	  mmHg	  
Substage	  1:	  low	  risk:	   	   	   systolic	  blood	  pressure	   	   	   150-­‐159	  mmHg	  
Substage	  2:	  moderate	  risk:	   	   systolic	  blood	  pressure	   	   	   160-­‐179	  mmHg	  
Substage	  3:	  high	  risk:	  	   	   systolic	  blood	  pressure	   	   ≥	  180	  mmHg	  
	  
Diagnosis	  
In	  chronic	  kidney	  disease	  the	  damage	  to	  the	  kidney	  is	  thought	  to	  be	  irreversible	  and	  the	  
compensatory	  mechanisms	  of	  the	  kidney	  are	  exhausted.	  In	  contrast,	  acute	  kidney	  injury	  is	  
potentially	  reversible.	  Therefore	  it	  is	  very	  important	  to	  differentiate	  between	  acute	  and	  chronic	  
kidney	  disease.	  In	  doubt	  a	  patient	  should	  be	  treated	  as	  a	  patient	  with	  acute	  kidney	  injury.	  The	  
causes	  of	  chronic	  kidney	  disease	  are	  often	  not	  known.	  Historical	  signs	  indicating	  chronic	  disease	  
include	  long	  lasting	  polyuria	  and	  polydipsia,	  decreased	  appetite,	  weight	  loss	  and	  poor	  hair	  coat	  
quality.	  On	  palpation	  the	  kidneys	  are	  typically	  small	  with	  an	  irregular	  surface.	  Enlarged	  kidneys	  are	  
also	  possible	  in	  certain	  kidney	  diseases.	  Anemia	  is	  common	  in	  chronic	  kidney	  disease;	  however	  
dehydration	  can	  mimic	  a	  normal	  hematocrit	  and	  anemia	  can	  be	  seen	  in	  acute	  kidney	  injury	  as	  well.	  
Differentiation	  between	  acute	  and	  chronic	  kidney	  disease	  can	  become	  even	  more	  difficult	  if	  an	  
acute	  kidney	  injury	  is	  added	  on	  top	  of	  a	  chronic	  disease.	  To	  differentiate	  acute	  from	  chronic	  kidney	  
disease,	  but	  also	  to	  find	  a	  specific	  underlying	  cause	  responsible	  for	  the	  chronic	  disease	  a	  full	  work	  
up	  is	  required.	  Blood	  and	  urine	  must	  be	  screened	  for	  underlying	  diseases.	  Urine	  culture	  might	  
detect	  a	  possible	  urinary	  tract	  infection.	  The	  urine	  protein:	  creatinine	  ratio	  might	  indicate	  the	  kind	  
of	  the	  kidney	  disease	  and	  is	  also	  a	  prognostic	  factor.	  With	  radiographs	  and/or	  ultrasound	  
examinations	  the	  kidneys	  can	  be	  evaluated,	  possible	  renal	  and	  extra	  renal	  causes	  of	  the	  kidney	  
damage	  like	  cystic	  kidney	  disease	  or	  ureteral	  obstruction	  can	  be	  detected	  or	  ruled	  out.	  High	  




If	  the	  cause	  of	  kidney	  disease	  or	  a	  related	  factor	  is	  identified	  during	  the	  work	  up	  this	  should	  be	  
treated	  accordingly.	  For	  instance	  a	  urinary	  tract	  infection	  is	  treated	  with	  the	  appropriate	  antibiotic	  
or	  obstruction	  of	  the	  ureter	  is	  relieved	  by	  an	  adequate	  intervention	  like	  stone	  removal	  or	  a	  
ureteral	  stent.	  Because	  of	  the	  reduced	  kidney	  function	  certain	  medications	  might	  not	  be	  
adequately	  excreted	  and	  a	  dose	  adjustment	  is	  necessary.	  However	  based	  on	  the	  level	  of	  the	  
kreatinine	  it	  is	  difficult	  to	  determine	  how	  much	  reduction	  is	  needed	  and	  if	  a	  reduction	  in	  dose	  or	  a	  
reduction	  in	  frequency	  of	  application	  is	  preferable.	  	  
	  
Reduction	  of	  phosphorus	  intake	  
If	  the	  GFR	  decreases,	  less	  phosphorus	  is	  filtrated	  and	  phosphorus	  accumulates	  in	  the	  body.	  In	  early	  
renal	  disease	  the	  decreased	  filtration	  is	  compensated	  by	  a	  decreased	  reabsorption	  in	  the	  tubules,	  
however	  at	  a	  certain	  point	  reabsorption	  can	  not	  be	  further	  reduced	  and	  the	  level	  of	  phosphorus	  
increases.	  Phosphorus	  is	  involved	  in	  the	  progression	  of	  kidney	  disease	  and	  is	  directly	  associated	  
with	  mortality	  from	  kidney	  disease.	  Furthermore	  phosphorus	  is	  one	  of	  the	  factors	  promoting	  renal	  
secondary	  hyperparathyreoidism.	  And	  finally	  high	  phosphorus	  contributes	  to	  a	  high	  calcium	  
phosphate	  product,	  which	  may	  lead	  to	  metastatic	  calcifications.	  Phosphorus	  should	  be	  measured	  
in	  all	  patients	  with	  chronic	  kidney	  disease.	  The	  level	  of	  serum	  phosphorus	  should	  ideally	  be	  below	  
the	  following	  values.	  
	  
IRIS	  stage	  2:	  	   serum	  phosphorus	   	  <	  1.45	  mmol/l	  
IRIS	  stage	  3:	  	   serum	  phosphorus	  	   <	  1.61	  mmol/l	  
IRIS	  stage	  4:	  	   serum	  phosphorus	  	   <	  1.94	  mmol/l.	  
	  
If	  dietary	  management	  does	  not	  adequately	  decrease	  the	  serum	  phosphorus	  intestinal	  phosphor	  
binding	  agents	  are	  indicated.	  Phosphorus	  binding	  agents	  on	  the	  basis	  of	  aluminum	  are	  effective	  in	  
cats;	  however	  it’s	  becoming	  more	  difficult	  to	  find	  them	  because	  aluminum	  toxicity	  is	  an	  issue	  in	  
human	  medicine.	  Alternative	  preparations	  are	  calcium-­‐carbonate,	  –acetate,	  or	  -­‐citrate	  and	  
lanthanum	  carbonate.	  One	  has	  to	  be	  cautious	  with	  calcium	  based	  phosphorus	  binding	  agents	  as	  
there	  is	  a	  risk	  of	  inducing	  hypercalcemia.	  These	  agents	  should	  not	  be	  given	  to	  hypercalcemic	  
patients	  and	  calcium	  should	  be	  monitored	  regularly.	  Dose	  recommendations	  for	  aluminum-­‐based	  
phosphorus-­‐binders	  are	  30	  to	  100	  mg/kg/d.	  For	  calcium	  acetate	  60	  to	  90	  mg/kg/d,	  for	  calcium	  
carbonate	  90	  to	  150	  mg/kg/d	  and	  for	  lanthanum	  carbonate	  about	  30	  mg/kg/d.	  The	  doses	  might	  
have	  to	  be	  increased	  if	  effect	  is	  not	  sufficient.	  Phosphorus-­‐binders	  should	  be	  given	  with	  the	  meal.	  
These	  agents	  only	  bind	  phosphorus	  in	  the	  food.	  If	  administered	  without	  food	  no	  effect	  is	  achieved.	  
	  
Therapy	  with	  calcitriol	  
The	  production	  of	  calcitriol	  is	  decreased	  in	  chronic	  kidney	  disease.	  This	  decrease	  is	  caused	  by	  
hyperphospahtemia,	  reduced	  renal	  mass	  and	  increased	  levels	  of	  fibroblast	  growth	  factor-­‐23	  (FGF-­‐
23).	  Calcitriol	  reduces	  PTH	  and	  enhances	  intestinal	  absorption	  of	  calcium	  and	  phosphorus	  and	  its	  
reduction	  plays	  an	  important	  role	  in	  the	  development	  of	  secondary	  hyperparathyroidism.	  
In	  cats	  calcitriol	  at	  a	  dose	  of	  2.5	  ng/kg/d	  had	  no	  effect	  on	  the	  level	  of	  PTH.	  If	  calcitriol	  is	  
administered,	  serum	  calcium	  levels	  should	  be	  closely	  monitored.	  Calcitriol	  can	  lead	  to	  
hypercalcemia	  which	  can	  lead	  to	  further	  kidney	  damage.	  
	  
Correction	  of	  anemia	  
Anemia	  in	  chronic	  kidney	  disease	  is	  caused	  by	  decreased	  erythrocyte	  live	  span,	  possible	  
gastrointestinal	  bleeding,	  and	  reduced	  production	  of	  erythropoietin.	  Quite	  often	  blood	  sampling	  
for	  diagnostic	  purposes	  is	  also	  involved	  in	  anemia.	  Anemia	  is	  a	  negative	  prognostic	  factor	  und	  
should	  be	  addressed.	  Iron	  deficiency	  although	  rarely	  thoroughly	  assessed	  might	  be	  a	  problem	  in	  
chronic	  renal	  disease.	  Iron	  supplementation	  with	  iron	  sulfate	  50	  to	  100	  mg/day	  and	  cat	  may	  be	  
started.	  However	  gastrointestinal	  derangements	  might	  occur.	  Iron	  dextran	  50	  mg/cat	  IM	  every	  3	  
to	  4	  weeks	  is	  an	  alternative.	  Together	  with	  iron	  or	  alone	  erythrocyte-­‐stimulating	  agents	  like	  the	  
recombinant	  human	  erythropoietin	  darbepoetin	  are	  used.	  Darbepoetin	  is	  started	  at	  a	  dose	  of	  1	  
mcg/kg	  weekly	  until	  the	  lower	  end	  of	  the	  reference	  range	  of	  the	  hematocrit	  is	  reached.	  After	  that	  
the	  interval	  is	  increased	  to	  every	  two	  then	  every	  three	  weeks.	  Besides	  these	  agents	  treatment	  of	  
possible	  gastrointestinal	  bleeding	  can	  be	  tried	  with	  for	  instance	  a	  proton	  pump	  inhibitor	  like	  
omeprazole	  (0.7	  mg/kg/d)	  and	  sucralfate	  (0.125-­‐0.5	  g/cat/d	  PO	  twice	  or	  three	  times	  a	  day).	  If	  
available	  a	  fast	  correction	  of	  anemia	  can	  be	  achieved	  with	  blood	  transfusion.	  	  
	  
Therapy	  of	  hypertension	  
Hypertension	  is	  associated	  with	  chronic	  kidney	  disease.	  Hypertension	  may	  lead	  to	  end-­‐organ	  
damage.	  Specifically	  vulnerable	  organ	  systems	  are	  the	  eyes	  the	  kidneys,	  the	  nervous	  system	  and	  
the	  cardiovascular	  system.	  In	  the	  kidneys	  high	  systemic	  blood	  pressure	  might	  be	  transmitted	  
directly	  to	  the	  glomeruli	  and	  lead	  to	  progression	  of	  the	  kidney	  disease.	  This	  may	  be	  exacerbated	  
by	  the	  fact	  that	  in	  damaged	  kidneys	  autoregulation	  is	  impaired	  leaving	  the	  glomerular	  blood	  
vessels	  unprotected	  from	  this	  high	  pressure.	  Hypertension	  is	  also	  associated	  with	  proteinuria	  
which	  leads	  to	  further	  kidney	  damage.	  Emergency	  treatment	  of	  hypertension	  is	  indicated	  if	  the	  
systolic	  blood	  pressure	  is	  above	  200	  mmHg	  or	  if	  end	  organ	  damage,	  most	  often	  blindness	  due	  to	  
retinal	  hemorrhage	  and	  detachment,	  is	  confirmed.	  However	  one	  must	  remember	  that	  the	  so	  
called	  “white	  coat	  effect”	  might	  induce	  a	  considerable	  increase	  in	  blood	  pressure	  and	  the	  
measured	  value	  does	  not	  represent	  the	  normal	  blood	  pressure.	  Therefore	  measurements	  should	  
be	  repeated	  at	  least	  three	  times	  at	  different	  days	  or	  even	  weeks.	  Treatment	  is	  started	  when	  
systolic	  arterial	  blood	  pressure	  consistently	  is	  above	  160	  mmHg	  (substage	  2).	  The	  treatment	  goal	  
would	  be	  to	  achieve	  a	  systolic	  blood	  pressure	  below	  150	  mmHg.	  Amlodipine	  is	  the	  most	  effective	  
drug	  for	  the	  reduction	  of	  blood	  pressure	  in	  cats.	  It	  also	  reduces	  proteinuria	  in	  cats	  likely	  due	  to	  the	  
reduction	  of	  the	  blood	  pressure.	  The	  starting	  dose	  usually	  is	  ⅛	  to	  ¼	  of	  a	  5	  mg	  tablet	  daily.	  After	  
institution	  of	  the	  therapy	  blood	  pressure	  is	  controlled	  every	  week	  until	  the	  desired	  reduction	  is	  
achieved.	  Hypotension	  should	  be	  avoided,	  as	  this	  might	  lead	  to	  decreased	  renal	  blood	  flow.	  Signs	  
of	  hypotension	  include	  weakness,	  lethargy	  and	  somnolence.	  
	  
ACE-­‐inhibitors	  
Progression	  of	  renal	  disease,	  independent	  of	  the	  original	  insult	  likely	  occurs	  in	  kidney	  disease	  of	  
stage	  2	  and	  higher.	  Reasons	  for	  this	  progression	  include	  intraglomerular	  hypertension	  in	  remaining	  
nephrons	  and	  proteinuria.	  Vasodilatation	  of	  the	  glomerular	  arterioles	  specifically	  the	  afferent	  in	  
the	  remaining	  nephrons	  leads	  to	  higher	  renal	  plasma	  flow	  and	  higher	  single	  nephron	  GFR	  but	  also	  
to	  intraglomerular	  hypertension.	  This	  higher	  pressure	  and	  flow	  leads	  to	  an	  enlarged	  glomerulus	  
damage	  of	  the	  endothelium,	  and	  to	  hypertrophy	  of	  the	  podocytes.	  This	  again	  promotes	  several	  
changes	  including	  proteinuria	  and	  accumulation	  of	  macromolecules	  in	  the	  mesangial	  area.	  
Proteinuria	  leads	  to	  progression	  of	  kidney	  disease	  by	  mesangial	  toxicity,	  tubular	  overload	  and	  
hyperplasia,	  tubular	  toxicity	  and	  induction	  of	  proinflammatory	  proteins.	  ACE-­‐inhibitors	  reduce	  the	  
intraglomerular	  pressure,	  proteinuria	  and	  the	  profibrotic	  effect	  of	  angiotensin	  II.	  In	  cats	  the	  ACE-­‐	  
inhibitor	  benazepril	  lead	  to	  a	  trend	  towards	  longer	  survival,	  showed	  potential	  to	  reduce	  
progression	  and	  reduced	  proteinuria	  in	  cats	  with	  chronic	  kidney	  disease.	  
Benazepril	  can	  be	  started	  at	  a	  dose	  of	  0.5	  mg/kg/d.	  Further	  studies	  are	  needed	  to	  evaluate	  if	  
blockade	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  system	  through	  angiotensin	  receptor	  blockade	  and	  
aldosterone	  blockade	  might	  be	  of	  more	  benefit	  in	  reducing	  progression	  of	  kidney	  disease	  in	  cats.	  
	  
Correction	  of	  metabolic	  acidosis	  
Diseased	  kidneys	  excrete	  less	  H+	  ions	  which	  can	  lead	  to	  metabolic	  acidosis.	  Metabolic	  acidosis	  can	  
lead	  to	  anorexia,	  vomitus,	  weakness	  and	  lethargy.	  Therefore	  it	  is	  important	  to	  evaluate	  the	  acid-­‐
base	  status	  of	  cats	  with	  chronic	  kidney	  disease.	  A	  total	  CO2	  of	  less	  than	  15	  mmol/L	  warrants	  
intervention.	  Most	  kidney	  diets	  are	  designed	  to	  reduce	  metabolic	  acidosis,	  however	  if	  this	  is	  not	  
enough	  sodium	  bicarbonate	  at	  a	  dose	  of	  8-­‐12	  mg/kg	  two	  to	  three	  times	  daily	  or	  potassium	  citrate	  
at	  a	  dose	  of	  40	  to	  60	  mg/kg	  two	  to	  three	  times	  daily	  are	  recommended.	  
	  
Medical	  management	  gastrointestinal	  complications	  
Uremia	  has	  a	  strong	  effect	  on	  the	  gastrointestinal	  tract.	  Clinical	  signs	  include	  anorexia,	  vomiting,	  
gastrointestinal	  bleeding	  and	  diarrhea.	  Uremia	  can	  lead	  to	  uremic	  stomatitis	  with	  ulcerations	  
brownish	  discoloration	  and	  necrosis	  of	  the	  tongue	  and	  halitosis	  further	  contributing	  to	  anorexia	  in	  
cats	  with	  chronic	  kidney	  disease.	  Symptomatic	  treatments	  for	  gastrointestinal	  complications	  
include	  the	  reduction	  of	  gastric	  hyperacidity,	  the	  reduction	  of	  nausea	  and	  the	  reduction	  of	  
gastrointestinal	  bleeding.	  Possible	  medications	  are	  omeprazole	  (0.7	  mg/kg/d)	  to	  reduce	  gastric	  
hyperacidity,	  sucralfate	  (0.125-­‐0.5	  g/cat/d	  PO	  twice	  or	  three	  times	  a	  day)	  to	  reduce	  
gastrointestinal	  bleeding,	  and	  maropintant	  (1	  mg/kg	  once	  daily,	  up	  to	  five	  days)	  or	  
metoclopramide	  (0.2-­‐0.4	  mg/kg	  IM,	  SC,	  PO	  three	  to	  four	  times	  daily)	  to	  reduce	  nausea.	  
	  
Correction	  of	  hypokalemia	  
Hypokalemia	  is	  common	  in	  cats	  with	  chronic	  kidney	  disease.	  Hypokalemia	  may	  lead	  to	  generalized	  
muscle	  weakness,	  anorexia	  and	  decreased	  renal	  function.	  Furthermore	  weight	  loss	  and	  poor	  hair-­‐
coat	  are	  associated	  with	  impaired	  protein	  synthesis	  due	  to	  hypokalemia.	  The	  main	  reasons	  for	  low	  
potassium	  are	  decreased	  intake	  and	  renal	  loss.	  Potassium	  can	  be	  supplemented	  with	  intravenous	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